Pfizer Unit Loses Patent Over Cancer Drug Compound
European officials nixed a Pfizer unit's patent for a brain cancer treatment, ruling that its new delivery method would have been obvious to scientists at the filing date based on previous...To view the full article, register now.
Already a subscriber? Click here to view full article